EUCTR2010-023396-25-PLActive, not recruitingNot Applicable
Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis - SMILE
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- SuppreMol GmbH
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Inclusion criteria 1.Patient has provided written informed consent prior to any study-related procedure 2.Male or female adult patients aged 18 years or older 3.Patients with a body weight between = 40 kg and = 100 kg 4.At least 4 criteria of the American College of Rheumatology (ACR) revised criteria (APPENDIX 1) documented in the medical history 5.A SELENA-SLEDAI score of at least 6 within 8 weeks prior to the first IP dosing. A subpopulation will fulfil in addition the following criteria for lupus nephritis: a) A history of class III, IV, or a combination of these with class V glomerulonephritis, within 60 months prior to first IP dosing confirmed by a renal biopsy according to the International Society of Nephrology (ISN) and the Renal Pathology Society (RPS) [APPENDIX 2]. The patient had never a pure class V or VI glomerulonephritis during the disease course AND b) Proteinuria between > 0.2 to = 3.5 g/day at SCR 6.Patients with a present serological active status defined as abnormal laboratory values from the last 2 local serum samples for the following parameters: a) serum antibodies against double-stranded DNA (anti-dsDNA) above upper limit of normal (ULN) OR/AND b) complement component 3 (C3) below lower limit of normal (LLN) Abnormality will be confirmed by a central laboratory during screening. 7.Patients with immunosuppressant SLE treatment (if any) other than listed under 8. have completed their SLE therapy prior to first IP dosing as follows: a) B-cell depleting agents (e.g. rituximab, epratuzumab, etc.) for = 48 weeks b) B-cell modifying agents (e.g. belimumab, atacicept, etc.) for = 24 weeks c) Intravenous immunoglobulins (IVIGs) for = 12 weeks d) All other immunosuppressive SLE treatment (e.g. metho-trexate, cyclophosphamide, cyclosporine, tacrolimus, etc.) for = 8 weeks 8.Patients with a stable maintenance immunosuppressant SLE treatment (if any) within 4 weeks prior to first IP dosing consisting of: = 20 mg/day prednisone (or equivalent) alone or in combination with either a) = 2 mg/kg/day azathioprine (AZA) OR b) = 2 g/day mycophenolate mofetil (MMF) [or equivalent] 9.The maintenance immunosuppressant SLE treatment is intended to remain stable during the clinical trial but at least within 4 weeks after the first IP dosing 10.Patients with a stable adjuvant maintenance SLE treatment (if any) such as antimalarias, angotensin-converting enzyme (ACE) inhibitors, non-steroid anti-inflammatory drugs (NSAIDs), cyclooxygenase inhibitors, anticoagulation- and antiplatelet agents, hormone replacement therapy, etc. within 4 weeks prior to first IP dosing. The adjuvant maintenance SLE treatment is intended to remain stable during the clinical trial but at least within 4 weeks after first IP dosing 11.Women of childbearing potential must have a negative serum pregnancy test within 3 weeks preceding the first dose of IP and a negative urine pregnancy test on study day 1 12.Both women of childbearing potential and men must use a medically acceptable method of contraception (APPENDIX 7) prior to inclusion, throughout the study, and within 12 weeks after IP discontinuation 13.Eastern Cooperative Oncology Group (ECOG) performance status = 2, with a life expectancy of at least 9 months (APPENDIX 8)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 47
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age ra
Exclusion Criteria
- •Exclusion 1.Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period 2.Patients with active SLE neurological disorder documented according to the ACR SLE criteria as listed in APPENDIX 1 within 12 weeks prior to first IP dosing 3.Patients with non-lupus related renal diseases or microthrombotic disease associated with antiphospolipid syndrome 4.Patients with known active retroviral infection such as as human immunodeficiency virus (HIV), hepatitis B or C 5.Patients with other acute infections (except minor infections such as common cold) within 4 weeks prior to first IP dosing 6.Patients with a glomerular filtration rate (GFR) of < 45 mL/min/1.73 m2 7.Patients with inadequate liver function expressed as at least one of the following: a) Aspartate aminotransferase (AST) > 3 times ULN OR b) Alanine aminotransferase (ALT) > 3 times ULN OR c) Serum bilirubin > 3 times ULN 8.Any kind of disorder that compromises the ability of the patient to give written informed consent and/or to comply with all study procedures 9.Known hypersensitivity to any recombinant E. coli-derived product or IP excipients (Polysorbat 20, Mannitol, Sucrose) 10.Patients participating in a concurrent clinical trial or treated with another IP within 4 weeks or five terminal half-lives (whichever is longer) prior to first IP dosing 11.History of alcohol or drug abuse within the previous 5 years 12.Any condition which in the judgment of the Investigator would place the patient at undue risk or interfere with the results of the study 13.Patients with an active malignancy 14.Patients with active, serious, life-threatening diseases
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023396-25-CZSuppreMol GmbH50
Active, not recruiting
Phase 1
A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)MedDRA version: 13.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023396-25-BESuppreMol GmbH50
Completed
Phase 2
SM101 In systemic lupus erythematosus patients with or without a history of lupus nephritisSystemic lupus erythematosusSystemic lupus erythematosus patients with or without a history of lupus nephritisMusculoskeletal DiseasesISRCTN84672048SuppreMol GmbH (Germany)50
Active, not recruiting
Phase 1
A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)MedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023396-25-GBSuppreMol GmbH50
Active, not recruiting
Not Applicable
A study to assess the safety and effectiveness of SL101 in the treatment of systemic lupus erythematosus (SLE)EUCTR2010-023396-25-DESuppreMol GmbH50